Enrico Ricevuto
Overview
Explore the profile of Enrico Ricevuto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
943
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gravina G, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, et al.
Int J Oncol
. 2025 Jan;
66(2.
PMID: 39749699
Following the publication of the above article, a concerned reader drew to the Editor's attention that certain of the western blot assay data shown in Fig. 4G on p. 717...
2.
Ricevuto E, Morgani C, Seri F, Bruera G
Asian J Androl
. 2024 Sep;
26(6):567-568.
PMID: 39327840
No abstract available.
3.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):68.
PMID: 39095493
No abstract available.
4.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):58.
PMID: 39019916
Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2- advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to...
5.
De Rocco S, Biasi J, Fantasia I, Tabacco S, Ricevuto E, Palumbo P, et al.
Diagnostics (Basel)
. 2024 Feb;
14(4).
PMID: 38396463
Primary pulmonary synovial sarcoma is a rare type of soft tissue tumor. Exceptionally it can occur during pregnancy, representing a challenge in management and treatment given its notable aggressiveness and...
6.
Guadagni S, Masedu F, Fiorentini G, Sarti D, Fiorentini C, Guadagni V, et al.
BMC Cancer
. 2022 Jun;
22(1):660.
PMID: 35710393
Background: Patients with unresectable recurrent rectal cancer (RRC) or colorectal cancer (CRC) with liver metastases, refractory to at least two lines of traditional systemic therapy, may receive third line intraarterial...
7.
Bruera G, Pepe F, Malapelle U, Di Staso M, Dal Mas A, Di Giacomo D, et al.
Ann Transl Med
. 2021 Jul;
9(12):1027.
PMID: 34277827
In fit metastatic colorectal cancer (MCRC), multidisciplinary treatment strategy integrating intensive FIr-B/FOx triplet chemotherapy associated to bevacizumab and secondary metastasectomies significantly improved clinical outcomes up to progression-free survival (PFS) 17...
8.
Bruera G, Ricevuto E
Pharmgenomics Pers Med
. 2020 Nov;
13:601-617.
PMID: 33235483
Evolving intensiveness of colorectal cancer (CRC) treatment, including chemotherapeutics and targeted agents associations, in adjuvant and metastatic CRC (MCRC) settings, increased overall survival (OS) with individual variability of toxicity. Pharmacogenomic...
9.
Guadagni S, Farina A, Cappabianca L, Sebastiano M, Maccarone R, Zelli V, et al.
Int J Mol Sci
. 2020 Nov;
21(21).
PMID: 33153070
Merkel cell carcinomas (MCCs) are rare, aggressive, cutaneous neuroendocrine tumours, approximately 80% of which are caused by the genomic integration of Merkel cell polyomavirus (MCPyV). MCPyV-positive MCCs carry poor prognosis...
10.
Bruera G, DAndrilli A, Simmaco M, Guadagni S, Rendina E, Ricevuto E
Front Oncol
. 2020 Aug;
10:1155.
PMID: 32850329
Intensive oncological treatment integrated with resection of metastases raised the clinical outcome of metastatic colorectal cancer (MCRC). In clinical practice, complex evaluation of clinical (age, performance status, comorbidities), and biological...